Health Economics›Non-small cell lung cancer squamous›Adjuvant therapy

Adjuvant therapy

Non-small cell lung cancer squamous · 1 regimen

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 1 point

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Cisplatin and Gemcitabine (GC) Variant #34	—	R 15 338	56d	~5.5 mo	~9.9 mo	~3	~R 46 014 PFS proxy · indirect	6

1 of 1 regimen shown